The effect of fennel fruit in treatment of abnormal uterine bleedings caused by polycystic ovarian syndrome

Clinical comparison of the effects of Foeniculum vulgare fruit and medroxyprogesterone in treatment of abnormal uterine bleedings in patients with polycystic ovarian syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138903013922N2

Enrollment

Registered

2015-02-04

Start date

2014-12-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrom. Sclerocystic ovary syndrome

Interventions

Intervention 1: In intervention group, aqueous extract of fennel fruit (capsule form) is given orally, 600 mg twice in a day for three consecutive months. Intervention 2: In control group, medroxyprog

Treatment - Drugs

In intervention group, aqueous extract of fennel fruit (capsule form) is given orally, 600 mg twice in a day for three consecutive months.

In control group, medroxyprogesterone is given orally, 5 mg twice in a day for 10 consecutive days during three consecutive menstrual cycles.

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: polycystic ovarian syndrome; abnormal uterine bleeding. Exclusion criteria: non-compliance to the plan.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Oligomenorrhea. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Hypermenorrhea. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Menorrhagia. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Polymenorrhagia. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Menometrorrhagia. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Metrorrhagia. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Amenorrhea. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.	—

Measure

Time frame

Oligomenorrhea. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Hypermenorrhea. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Menorrhagia. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Polymenorrhagia. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Menometrorrhagia. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Metrorrhagia. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.;Amenorrhea. Timepoint: the first day of the study, 90th day. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Masoud Modarresi

Kermanshah University of medical Sciences, Faculty of Pharmacy

mmodarresi@kums.ac.ir+98 83 3427 6482

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026